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Time to rethink approaches to migrant health screening
The elimination of tuberculosis in Europe is a key public 
health priority,1 yet unprecedented levels of migration, 
especially from low-income or middle-income countries, 
pose challenges to achieving this goal. The overall 
incidence of tuberculosis in migrants is increasing 
in several countries, and—for example—migrants 
comprise more than 70% of all newly diagnosed cases 
in the UK, Sweden, the Netherlands, and Norway.2 
Migrants are at higher risk of clinical tuberculosis as a 
result of coming from countries with a high burden of 
infection, the poverty they might face on arrival, and a 
plethora of barriers to accessing free statutory health 
care and screening.3 Yet what constitutes a cost-eﬀ ective 
approach to migrant screening and understanding what 
to screen for, and who, where, and when to screen, 
remain contentious.
In The Lancet, Robert W Aldridge and colleagues4 
report the ﬁ ndings of a large retrospective cohort study 
of more than half a million migrants requesting a long-
term entry visa to the UK (2005–12) who were screened 
for active tuberculosis in 15 high-incidence countries 
of origin before migration. Pre-entry screening 
data for this cohort are published elsewhere.5 In the 
present study, the researchers explored what happens 
to migrants, free from active disease at the time of 
migration, after their arrival to the UK (mean follow-
up 2·45 years per person). This research is timely, amid 
growing consensus that identiﬁ cation and treatment 
of latent tuberculosis before the disease becomes active 
could support elimination eﬀ orts,6,7 representing a shift 
from the historical Europe-wide approach of screening 
for active disease on, or soon after, arrival. 
Aldridge and colleagues report that migrants 
screened before entry pose a negligible public health 
risk in terms of onward transmission (only 35 assumed 
index cases with an estimated crude rate of ﬁ ve per 
100 000 person-years [95% CI 4–8]) but are at risk of 
developing active tuberculosis after arrival to the UK, 
with 79·6% of cases notiﬁ ed after migration. The 
incidence of all forms of tuberculosis was lowest in the 
ﬁ rst year after arrival, and then peaked in the fourth 
year (222 per 100 000 person-years [95% CI 198–249]) 
before declining, with many cases resulting from 
reactivation of latent infection (301 cases with crude 
estimated incidence of 46 per 100 000 person-years 
[95% CI 42–52]). The data show, not unexpectedly, 
that some groups of migrants were over-represented 
among reactivation cases, including migrants from 
high-incidence countries (ie, countries with >350 cases 
per 100 000 people) and those with a chest radiograph 
compatible with tuberculosis but not bacteriologically 
conﬁ rmed when pre-screened in their countries of origin. 
Why the authors did not address the extent to which 
key risk factors such as socioeconomic deprivation in 
the host country and comorbidities (eg, HIV, diabetes 
mellitus) drive tuberculosis reactivation is unclear.
Although these data are limited to a particular subset 
of migrants requesting a long-term entry visa to the UK, 
they have potential implications for screening policies 
for the wider population of migrants across Europe, 
and suggest that screening and treatment for latent 
tuberculosis in migrants from high-incidence countries 
before departure, and within 5 years of arrival in the host 
country, could strengthen control eﬀ orts. This approach 
is likely to be cost-eﬀ ective.6,7
Aldridge and colleagues’ data support the notion 
that to eliminate tuberculosis in low-burden settings 
multiple initiatives will be needed. The UK is one of a few 
European countries now screening individuals before 
they migrate,8 and is pioneering a national strategy for 
latent tuberculosis testing in newly arrived migrants.9,10 
We strongly support innovations in migrant screening 
and health-care delivery. However, policy makers need 
to be aware that thousands of migrants in the UK 
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and Europe—including refugees, asylum seekers, and 
undocumented migrants from high-incidence countries—
will completely bypass national screening programmes. 
Underlying all these new developments in the ﬁ eld of 
migrant health care, therefore, is the crucial need for 
innovative strategies to improve migrants’ access to host 
health systems, which will ensure timely screening for not 
only tuberculosis, but also other common infections that 
disproportionately aﬀ ect migrants, as well as delivery of 
vaccinations and aﬀ ordable health care and treatment. 
We, for example, are exploring one-stop testing for latent 
tuberculosis, hepatitis B and C virus infections, and HIV 
through emergency departments, where a high number 
of migrants are thought to present. 
Another essential consideration is that once screened, 
poor follow-up and low treatment completion rates 
are well documented in migrant patients—particularly 
for latent tuberculosis—which might render screening 
programmes ineﬀ ective and will necessitate unique 
approaches.2,11 Although the evidence base is 
incomplete, the European Centre for Disease Prevention 
and Control is currently developing much-awaited 
guidance on migrant screening.12 Aldridge and 
colleagues’ study therefore is a welcome contribution 
to evolving policy discussions around improving health 
outcomes in migrants across Europe. 
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